Abstracts tagged "depression"

Abstract Number: 022 • 2023 Pediatric Rheumatology Symposium
Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias
aviya lanis, Natalie Rosenwasser and Esi Morgan, Seattle Children's Hospital, Seattle, WA
Background/Purpose: Burnout, a syndrome of emotional exhaustion and depersonalization, adversely impacts healthcare. This can result in mood disturbances, poor patient and provider satisfaction and high…
Abstract Number: 057 • 2023 Pediatric Rheumatology Symposium
A “High-Risk” Depression/Fatigue Profile May Be Associated with Stronger Response to a Psychological Treatment for Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Elizabeth Ross¹, khalid abulaban², Elizabeth Kessler², Andrea Knight³ and Natoshia Cunningham⁴, ¹Michigan State University College of Human Medicine, Grand Rapids, MI, ²Helen DeVos Children's Hospital, Grand Rapids, MI, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Michigan State University, Grand Rapids, MI
Background/Purpose: Children with childhood-onset systemic lupus erythematosus (cSLE) experience more severe disease than their adult counterparts, in addition to high rates of clinical depressive symptoms…
Abstract Number: 058 • 2023 Pediatric Rheumatology Symposium
High Levels of Psychological Distress, Depression, and Anxiety Symptoms in Children with Pediatric Rheumatologic Diseases
Natalie Rosenwasser¹, Tamar Rubinstein², Andrea Knight³, Natoshia Cunningham⁴, Aimee Hersh⁵, Vincent Del Gaizo⁶ and Erin Treemarcki⁵, ¹Seattle Children's Hospital, seattle, WA, ²Children's Hospital at Montefiore, New York, NY, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Michigan State University, Grand Rapids, MI, ⁵University of Utah, Salt Lake City, UT, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ
Background/Purpose: Mental health problems are common in children with pediatric rheumatologic diseases (PRDs) and are associated with worsened quality of life and poorer disease-related outcomes.…
Abstract Number: 1785 • ACR Convergence 2022
PROs and Sociodemographic Factors in Year Prior to COVID Predict Trajectories of Depressive Symptoms in Adults with RA in First 2 Years of Pandemic: Data from the Canadian Early Arthritis Cohort
Susan Bartlett¹, orit schieir², Marie-France Valois², Janet Pope³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Carter Thorne⁸, Diane Tin⁹, Glen Hazlewood¹⁰ and Vivian Bykerk¹¹, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY
Background/Purpose: Growing evidence points to considerable mental health impacts of the prolonged COVID-19 pandemic, though data from longitudinal studies in rheumatic diseases are sparse. We…
Abstract Number: 0201 • ACR Convergence 2022
Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
Maurice Flurie¹, Joseph Coe², Monica Converse¹, Kristina Davidson³, Colton Flowers¹, Kelly Gavigan⁴, Daniel Hernandez⁵, Helen Hernandez¹, Gary Ho⁶, Brian LaMoreaux³, Christopher Parker⁶, E. Robert Wassman¹, Christopher DeFelice¹ and Maria Picone¹, ¹TREND Community, Philadelphia, ²Global Healthy Living Foundation, Upper Nyack, ³Horizon Therapeutics, Chicago, IL, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Gout Support Group of America, Austin, TX
Background/Purpose: The ability to actively listen to and interpret the patient experience is vital to effectively address the needs of individuals within a particular community.…
Abstract Number: 1908 • ACR Convergence 2022
Should Osteoarthritis Patients with Pain Scores More Than 8/10 Be Analyzed Separately or Excluded from Clinical Trial Protocols, as 72% Screen Positive for Fibromyalgia And/or Depression on a Multidimensional Health Assessment Questionnaire (MDHAQ)?
Juan Schmukler¹, Kathryn Gibson², Tengfei Li³, Joel Block¹ and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Most osteoarthritis (OA) clinical trial protocols require a 0-10 pain visual numeric scale (VNS) or other quantitative pain score of 4/10 or more for…
Abstract Number: 0204 • ACR Convergence 2022
Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment
Jessica Leung¹, Claire Owen², David Liew³ and Russell Buchanan³, ¹Austin Health, Preston, Victoria, Australia, ²Austin Health, Malvern East, Australia, ³Austin Health, Heidelberg, Australia
Background/Purpose: Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients…
Abstract Number: 1910 • ACR Convergence 2022
Evaluation of Dynamic Effects of Depressive Symptoms on Functional Outcomes in Knee Osteoarthritis
Rhea Mehta¹, Marc Hochberg², Michelle Shardell¹, Alice Ryan¹, Yu Dong¹, Brock Beamer¹, Jason Peer², Megan Schuler³, Joseph Gallo⁴, Elizabeth Stuart⁴ and Alan Rathbun¹, ¹University of Maryland, School of Medicine, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD, ³Rand Inc., Boston, MA, ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Knee OA is a leading cause of functional decline, and psychiatric comorbidity is common, particularly major depression. Depressive symptoms decrease physical activity and exacerbate…
Abstract Number: 0250 • ACR Convergence 2022
Performance of Fear Assessment in Inflammatory Rheumatic Diseases (FAIR) Questionnaire in a Cohort of Rheumatoid Arthritis Patients in Argentina
Jose Simon Alcivar-Navarrete¹, Joan Manuel Dapeña¹, Juan Manuel Bande¹, Eliana Rebeca Serrano¹, Maria Alejandra Medina¹, Diana Silvia Klajn¹, Jose Angel Caracciolo¹, Analia Dellepiane², Maria Paula Kohan³, Maria Julia Sosa³, maria de los angeles correa⁴, Maximiliano Machado Escobar⁵, Maria Silvia Yacuzzi⁵, Debora Guaglianone⁶, Mariana Benegas⁷, Emel de Jesus Gonzalez Lobato⁸, Eduardo Kerzberg⁸, Sandra Petruzzeli⁹, Beverly De la Puente Perez¹⁰ and Silvia Beatriz Papasidero¹, ¹Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, ²Centro de Especialidades Medicas Caseros, Casilda, Argentina, ³Hospital Dr. Raul F. Larcade, San Miguel, Buenos Aires, Argentina, ⁴Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Hospital Eva Peron, Banda del Rio Sali, Argentina, ⁶Hospital Provincial de Rosario, Rosario, Santa Fe, Argentina, ⁷Sanatorio Dr. Julio Mendez, Buenos Aires, Argentina, ⁸Hospital General de Agudos Dr. Ramos Mejia, Buenos Aires, Argentina, ⁹Casa Hospital San Juan de Dios, Ramos Mejia, Buenos Aires, Argentina, ¹⁰Hospital General de Agudos Dr. Jose Maria Penna, Buenos Aires, Argentina
Background/Purpose: RA is a systemic disease that can compromise many aspects of patient health. The increased psychological burden of RA is known and multifactorial, recent…
Abstract Number: 0697 • ACR Convergence 2022
Are Fibromyalgia and Depression as Common as Any Primary Diagnosis in Routine Rheumatology Care, Albeit as Secondary Diagnoses, but Which May Confound Clinical Assessment?
Theodore Pincus¹, Kathryn Gibson², Juan Schmukler¹, Tengfei Li³ and Joel Block¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Fibromyalgia (FM) and depression (DEP) are common comorbidities of all reported primary rheumatic diagnoses, easily recognized in many patients, but often underestimated, particularly in…
Abstract Number: 0733 • ACR Convergence 2022
Median Patient Global Assessment Varies Far More According to FAST4 (fibromyalgia Assessment Screening Tool) and MDS2 (MDHAQ Depression Screen) on a Single MDHAQ (multidimensional Health Assessment Questionnaire) Than According to Primary Diagnosis
Theodore Pincus¹, Kathryn Gibson², Juan Schmukler¹, Tengfei Li³ and Joel Block¹, ¹Rush University Medical Center, Chicago, IL, ²Liverpool Hospital, Sydney, Australia, ³Georgetown University, Washington, DC
Background/Purpose: Patient global assessment (PATGL) is a component of DAS28 (disease activity score 28) and CDAI (clinical disease activity index) to assess patients with rheumatoid…
Abstract Number: 0886 • ACR Convergence 2022
Incidence of Depression and Anxiety in Rheumatoid Arthritis Patients over Three Decades: A Population-Based Study
Rachel Giblon¹, Sara Achenbach², Elena Myasoedova¹, John Davis¹, Vanessa Kronzer¹ and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³Mayo Clinic, Eyota, MN
Background/Purpose: Depression and anxiety are known to occur more commonly in patients with RA. For example, recent studies estimate a depression point-prevalence of 17% in…
Abstract Number: 0902 • ACR Convergence 2022
Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method
Yusuke Miwa¹, Yuko Mitamura², Hiroi Tomioka³ and Michio Hosaka⁴, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²Department of Nursing, Showa University School of Nursing and Rehabilitation Sciences, Tokyo, Japan, ³Department of Psychiatry, School of Medicine, Yokohama, Japan, ⁴Department of psychosomatic medicine, Fujiyoshida, Japan
Background/Purpose: It has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods.…
Abstract Number: 1021 • ACR Convergence 2022
Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis
Rebecca Haberman¹, Seungha Um², Sydney Catron¹, Eileen Lydon³, Malavika Attur², Andrea Neimann², Soumya Reddy⁴, Andrea Troxel¹, Samrachana Adhikari¹ and Jose Scher⁵, ¹NYU Langone Health, New York, NY, ²NYU Langone, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex immune-mediated disease. Beyond its deleterious effects in the skin and joints, PsA can lead to decreased quality of…
Abstract Number: 1050 • ACR Convergence 2022
Clinically Recognized Depression and Mental Health Treatment in a Single Center Cohort of Patients with Systemic Sclerosis
Marissa Savoie¹, Alexandra Poeschla¹, na lu², Yuqing Zhang³, Marcy Bolster¹, Sara Schoenfeld¹ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²Arthritis Research Canada, Boston, MA, ³Massachusetts General Hospital, Quincy, MA
Background/Purpose: The prevalence of depression among patients with systemic sclerosis (SSc) is 35-65%1, yet little is known about mental health care utilization in SSc. It…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].